Navigation Links
Spherix Announces 2008 Financial Results
Date:3/30/2009

>About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries--Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopha
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Toronto, Canada (PRWEB) August 01, 2014 ... what should it cost? This webinar will discuss how ... construction. , Join speakers Bob Allen, Senior Director ... Director of Process Engineering at Fluor Industrial Services, and ... supporting Manufacturing Asset Planning at Amgen, as they provide ...
(Date:8/1/2014)... 2014 Testing the mechanical properties ... better understanding embryonic development. How and why ... and functionally distinct tissues is important because abnormalities ... Todd McDevitt, Melissa Kinney, and Rabbia Saeed worked ... biochemical cues to control many aspects of embryo ...
(Date:7/31/2014)... Nearly 20,000 medical professionals and healthcare leaders gathered for ... Expo in Chicago from July ... and technology that will advance medicine and get patients ... July 30, more than 19,500 attendees had registered for ... with more than 10,000 of these attendees coming for ...
(Date:7/31/2014)... have mapped the sound-processing part of the mouse brain ... and the trees in view. Their imaging technique allows ... within mice, and it enabled the team to watch ... other. The results, which represent a step toward better ... July 31 the journal Neuron . , In ...
Breaking Biology Technology:Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Study Links Biomechanics and Gene Expression in Stem Cells 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2
... , 3Q09 Corporate Highlights: , ... Europe Ltd. Made significant progress in commercial readiness ... Director, Marketing; and Director, Commercial Operations Appointed Bradford S. ... , Upcoming 2009 Milestones: , ...
... Nov. 6 Intarcia Therapeutics, Inc. delivered two presentations ... exenatide) program for the treatment of type 2 diabetes ... Francisco, CA: , (Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) , ... Lowers Plasma Glucose, HbA1c and Reduces Weight in a ...
... , GAITHERSBURG, Md., Nov. 5 GenVec, Inc. (Nasdaq: GNVC ... September 30, 2009. GenVec reported a net loss of $3.6 million ... compared to a net loss of $6.8 million ($0.08 per share) ... September 30, 2009, GenVec,s net loss was $14.1 million ($0.15 per ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
(Date:7/31/2014)... first-of-its-kind study of bigeye tuna movements in the northwestern ... Large Pelagics Research Center at the University of Massachusetts ... a wide geographical range with pronounced north-south movements from ... a high-use area off Cape Hatteras southwest of Bermuda ... new approach to study one of the most important ...
(Date:7/31/2014)... U.S. Census Bureau, Latinos are the largest minority group ... Approximately one-third of Latinos are obese and are ... non-Hispanic Whites. , NYU College of Nursing student ... to identify the factors that contribute to this problem ... focused on food patterns in Latina women recently published ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
Breaking Biology News(10 mins):Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... fever wax and wane over a period of several ... the incidence and range of the potentially deadly mosquito-borne ... has never been more important. , A new study ... a brief period of cross-immunity conferred by any one ...
... led by a conservationist from the Bronx Zoo-based Wildlife ... European Union project CURESS near Chad's Zakouma National Park, ... only their tusks -- a sure sign that poaching ... protected area. , Mike Fay, a WCS conservationist and ...
... genes with a single injection into a vein holds ... heart, University of Florida researchers report. , UF researchers ... with a form of muscular dystrophy that damages the ... monkeys and found genes were readily absorbed by heart ...
Cached Biology News:UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3Widespread elephant slaughter discovered in Chad 2UF scientists test improved gene therapy method for hereditary heart conditions 2UF scientists test improved gene therapy method for hereditary heart conditions 3UF scientists test improved gene therapy method for hereditary heart conditions 4
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Phospho-C/EBPbeta (Thr235) Antibody...
Biology Products: